Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Ligand Pharmaceuticals's enterprise value was $4.95B on Nov 11, 2026, against $3.33B a year earlier. Over the last 5 years it ranged from $688.30M to $5.55B, with a median of $1.64B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $4.95B | +62.3% |
| 2025 | Dec 31, 2025 | $3.05B | +70.4% |
| 2024 | Dec 31, 2024 | $1.79B | +70.0% |
| 2023 | Dec 29, 2023 | $1.05B | +4.6% |
| 2022 | Dec 30, 2022 | $1.01B | -55.4% |
| 2021 | Dec 31, 2021 | $2.26B | +180.4% |
| 2020 | Dec 31, 2020 | $804.99M | – |
| 2019 | Dec 31, 2019 | -$1.10B | -160.6% |
| 2018 | Dec 31, 2018 | $1.81B | -32.5% |
| 2017 | Dec 29, 2017 | $2.69B | +34.4% |
| 2016 | Dec 30, 2016 | $2.00B | +1.4% |
| 2015 | Dec 31, 2015 | $1.97B | +123.5% |
| 2014 | Dec 31, 2014 | $882.25M | -21.9% |
| 2013 | Dec 31, 2013 | $1.13B | +152.0% |
| 2012 | Dec 31, 2012 | $448.08M | +85.8% |
| 2011 | Dec 30, 2011 | $241.13M | +58.4% |
| 2010 | Dec 31, 2010 | $152.23M | – |
See a number that looks wrong?